Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
3.300
-0.020 (-0.60%)
At close: Mar 2, 2026, 4:00 PM EST
3.270
-0.030 (-0.91%)
Pre-market: Mar 3, 2026, 5:27 AM EST
Cabaletta Bio Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Cabaletta Bio stock have an average target of 14.57, with a low estimate of 2.00 and a high estimate of 30. The average target predicts an increase of 341.52% from the current stock price of 3.30.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 31, 2025.
Analyst Ratings
The average analyst rating for Cabaletta Bio stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $15 → $30 | Buy | Maintains | $15 → $30 | +809.09% | Oct 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +384.85% | Oct 10, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $15 | Buy | Reiterates | $15 | +354.55% | Sep 5, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $13 → $10 | Strong Buy | Maintains | $13 → $10 | +203.03% | Aug 14, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $25 → $15 | Strong Buy | Maintains | $25 → $15 | +354.55% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.17
from -2.36
EPS Next Year
-1.81
from -2.17
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.56 | -1.23 | ||||
| Avg | -2.17 | -1.81 | ||||
| Low | -2.41 | -2.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.